The company says that it aims to have the gel act as a much more user friendly alternative to traditional gauze and bandages. Credit: Shutterstock / MAKSYM CHUB

The US Food and Drug Administration (FDA) has granted market clearance to a medical gel designed to stem bleeding in emergency situations.

The FDA has granted New York-based company, Cresilon, a second 510(k) clearance for the plant-based gel, known as Traumagel, for the temporary external use for controlling moderate to severe bleeding, with the aim of supplying it to the US armed forces and emergency services. The company received a first clearance in June 2023, for local management of bleeding wounds.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

According to Cresilon, the gel is designed to directly stem the bleeding of wounds caused by severe trauma, for example, a gunshot wound, with the gel hardening on contact to form a seal around the point of injury.

Research published by the US National Institutes of Health (NIH) found trauma to be the leading cause of death worldwide among people younger than 44. Up to 60% of those who die from blood loss stemming from a traumatic injury pass within the first three hours following the incident. Cresilon hopes that its trauma gel will be used in place of traditional gauze and bandages.

Joe Landolina, CEO, and co-founder of Cresilon said: “The ability to rapidly stop bleeding at the point of care and halt a life-threatening haemorrhage can be the difference between life and death for people with traumatic wounds.

“The FDA clearance for Traumagel is a monumental milestone for Cresilon and brings us another step forward in our mission to save lives and transform the standard of care in wound treatment. Our proprietary hemostatic gel technology is a game-changer and unlike any other hemostatic agent currently being used.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

A market growth model by GlobalData estimates that the wound care management market will be worth nearly $39bn by 2030. Previously the gel had been given the greenlight to be used in the veterinary industry before receiving clearance from  the FDA for its first human use in June 2023.

In July  2024, the company completed the first phase of a preclinical study alongside the US Department of Defense (DOD) examining the impact of the gel in the treatment of head and brain injury.